Results 101 to 110 of about 22,643,381 (355)

TREATMENT OF HEMOPHILIA WITH HUMAN FACTORIX PRODUCED IN MAMIMARY TISSUE OF TRANSGENIC MAMMALS [PDF]

, 2008
Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention.
Drohan, William N., Johnson, John L., Johnson, Mary Ann H., Lubon, Henryk, Velander, William H.   +4 more
core   +1 more source

Investigating the role of SARM1 in central nervous system

Ibrain, EarlyView.
Sterile‐α and Toll/interleukin 1 receptor (TIR) motif‐containing protein 1 (SARM1) is a pivotal molecule that has garnered extensive attention in neuroscience. As an intracellular molecule, SARM1 possesses various crucial biological functions in the nervous system.
Junjie Wang, Yuhang Shi, Jinglei Tian, Liming Tang, Fang Cao   +4 more
wiley   +1 more source

Emergency department visits in children with hemophilia [PDF]

, 2012
Background The pediatric emergency department (ED) management of bleeding and other complications of hemophilia constitutes an increasingly important component of hemophilia therapy.
Callaghan, Michael U., Chitlur, Meera, Lusher, Jeanne M., Rajpurkar, Madhvi, Zia, Ayesha, Özgönenel, Bülent   +5 more
core   +1 more source

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

The Journal of Clinical Pharmacology, EarlyView.
Abstract Efanesoctocog alfa is a first‐in‐class high‐sustained factor VIII (HSF) replacement therapy for treatment of hemophilia A. This article presents population pharmacokinetics (PopPK) of efanesoctocog alfa and repeated time‐to‐event (RTTE) analysis of bleeding episodes in adults/adolescents (≥12 years of age) and children (<12 years).
Nancy Wong, Pratik Bhagunde, Joakim Nyberg, Suresh Katragadda, Marek Demissie, Annemieke Willemze, Craig Benson, Sreeraj Macha   +7 more
wiley   +1 more source

A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]

, 2015
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H., Ahmadinejad, M., Baghaeipour, M.R., Dehdezi, B.K., Eshghi, P., Faranoush, M., Fayazfar, R., Heshmat, R., Hoorfar, H., Kamyar, K., Karimi, M., Khoeiny, B., Managhchi, M., Mehrvar, A., Mirbehbahani, N.B., Naderi, M., Toogeh, G.   +16 more
core  

Hypoxic Preconditioning Enhances Survival and Proangiogenic Capacity of Human First Trimester Chorionic Villus-Derived Mesenchymal Stem Cells for Fetal Tissue Engineering. [PDF]

, 2019
Prenatal stem cell-based regenerative therapies have progressed substantially and have been demonstrated as effective treatment options for fetal diseases that were previously deemed untreatable. Due to immunoregulatory properties, self-renewal capacity,
Farmer, Diana L, Guo, Fuzheng, Hao, Dake, He, Chuanchao, Lankford, Lee, Ma, Bowen, Reynaga, Lizette, Wang, Aijun   +7 more
core   +1 more source

Hemophilia of orbit

Oman Journal of Ophthalmology, 2009
Hemophilic pseudotumor is an uncommon complication of factor VIII and IX deficiencies in the coagulation cascade and occurs in a wide spectrum of bones and soft tissues. We present a six-year-old boy with hemophilic pseudotumor localized in the right orbit.
Pooja Sethi, Gunaseelan Karunanithi, Vivekanandam, Sathyanarayana Kanipakapatanam Reddy   +3 more
openaire   +3 more sources

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects

TH Open, 2019
Background Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity.
Raimondo De Cristofaro, Monica Sacco, Stefano Lancellotti, Federico Berruti, Isabella Garagiola, Carla Valsecchi, Maria Basso, Enrico Di Stasio, Flora Peyvandi   +8 more
doaj   +1 more source

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Journal of Thrombosis and Haemostasis, 2019
Recombinant activated factor VII (rFVIIa; eptacog alfa activated, NovoSeven®, Novo Nordisk A/S) is a bypassing agent used in congenital hemophilia A patients with inhibitors.
G. Levy, E. Asikanius, P. Kuebler, S. Benchikh El Fegoun, Sille Esbjerg, S. Seremetis   +5 more
semanticscholar   +1 more source

Very low dislocation rate and good clinical outcome after Bereiter trochleoplasty and additional procedures following the Copenhagen patella–femoral instability algorithm: One‐ and two‐years outcomes from a consecutive cohort of 368 cases

Knee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose Patello–femoral instability (PFI) is often caused by predisposing factors, with trochlea dysplasia (TD) as the most prominent. Untreated patellar instability leads to impaired function and an increased risk of patellofemoral osteoarthritis.
Christian Dippmann, Volkert Siersma, Simone Rechter, Kristoffer W. Barfod, Peter Lavard   +4 more
wiley   +1 more source